Summary

for people ages 18 years and up (full criteria)
at La Jolla, California and other locations
study started
estimated completion

Description

Summary

This study will evaluate the long-term safety and efficacy of Bimatoprost SR in patients with open-angle glaucoma or ocular hypertension who completed 1 of the 4 Phase 3 Bimatoprost SR studies (192024-091, -092, -093, or -095) and received Bimatoprost SR.

Official Title

An Extension Trial to Evaluate the Long-term Safety and Efficacy of Bimatoprost SR in Patients With Open Angle Glaucoma or Ocular Hypertension

Keywords

Open-Angle Glaucoma Ocular Hypertension Glaucoma Glaucoma, Open-Angle Hypertension Bimatoprost Bimatoprost SR Bimatoprost SR 10mcg; Lead-in study 192024-093 Bimatoprost SR 15mcg; Lead-in studies 192024-093/-095 Bimatoprost SR 10mcg; Lead-in studies 192024-091/-092 Bimatoprost SR 15mcg; Lead-in studies 192024-091/-092

Eligibility

You can join if…

Open to people ages 18 years and up

  • Patients who completed 1 of the 4 Bimatoprost SR Phase 3 studies (192024-091, -092, -093, or -095) and received Bimatoprost SR

You CAN'T join if...

  • Female patients who are pregnant, nursing, or planning a pregnancy, or who are of childbearing potential and not using a reliable means of contraception during the study
  • Concurrent or anticipated enrollment in another investigational drug or device study during the present study
  • Any condition which would preclude the patient's ability to comply with study requirements, including completion of the study
  • Patients who were randomized to receive timolol eye drops in the study eye (control group) during the Phase 3 Bimatoprost Studies 192024-091 and -092

Locations

  • Hamilton Glaucoma Center, Shiley Eye Center UCSD
    La Jolla California 92037 United States
  • Lakeside Vision Center
    Irvine California 92604 United States
  • Eye Research Foundation
    Newport Beach California 92663 United States